kabutan

Kubota Pharmaceutical Holdings Co., Ltd.(4596) Summary

4596
TSE Growth
Kubota Pharmaceutical Holdings Co., Ltd.
94
JPY
-1
(-1.05%)
Apr 28, 3:30 pm JST
0.59
USD
Apr 28, 2:30 am EDT
Result
PTS
outside of trading hours
92.7
Apr 28, 11:56 pm JST
Summary Chart Historical News Financial Result
PER
PBR
7.18
Yield
ー%
Margin Trading Ratio
Stock Price
Apr 28, 2026
Opening Apr 28, 9:00 am
95 JPY 0.59 USD
Previous Close Apr 27
95 JPY 0.59 USD
High Apr 28, 9:00 am
96 JPY 0.60 USD
Low Apr 28, 11:00 am
92 JPY 0.57 USD
Volume
1,419,400
Trading Value
0.13B JPY 0.83M USD
VWAP
93.6 JPY 0.59 USD
Minimum Trading Value
9,400 JPY 59 USD
Market Cap
0.01T JPY 0.08B USD
Number of Trades
557
Liquidity & Number of Trades
As of Apr 28, 2026
Liquidity
High
1-Year Average
1,216
1-Year High Sep 3, 2025
18,100
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 24, 2026 0 6,205,900
Apr 17, 2026 0 5,858,500
Apr 10, 2026 0 6,044,100
Apr 3, 2026 0 5,644,200
Mar 27, 2026 0 5,848,500
Company Profile
Kubota Pharmaceutical Holdings Co., Ltd. is a venture company focused on developing treatments for eye diseases. The company is currently concentrating on developing corrective glasses for myopia. Drug development projects have been suspended.
Sector
Pharmaceuticals
Kubota Pharmaceutical Holdings Co., Ltd. is committed to developing innovative treatments and medical technologies as an ophthalmic medical solutions company. The company aims to contribute to maintaining and restoring vision for patients with eye diseases by developing and commercializing innovative pharmaceuticals and medical devices. Their main focus is in the medical device field, with emphasis on the "Kubota Glass," a wearable device for myopia control using proprietary active stimulation technology. They are also developing "eyeMO," an ultra-compact OCT for home-based ophthalmic care. In the small molecule compound area, they are advancing the development of emixustat hydrochloride as a treatment for Stargardt disease, based on visual cycle modulation technology. The company is actively pursuing partnership strategies with other companies to expand their pipeline and is also exploring M&A opportunities.